GMP/FDA requirements to aseptic production

被引：0

|

作者：

Langer, U

Mangel, A

机构：

[1] Concept Heidelberg, D-69007 Heidelberg, Germany

[2] Univ Mainz Klinikum, Mainz, Germany

来源：

PHARMAZEUTISCHE INDUSTRIE | 2002年 / 64卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

收藏

页码：375 / 383

页数：9

相关论文

共 50 条

[31] Requirements on safety, versatility and performance of isolators in the production of aseptic parenterals - A contribution on the duties of dealt room isolators
Sirch, E
PHARMAZEUTISCHE INDUSTRIE, 1996, 58 (01): : 67 - 77
[32] GMP in vaccine production
Hietava, M
34TH R3-NORDIC CONTAMINATION CONTROL SYMPOSIUM, 2003, 229 : 247 - 247
[33] GMP requirements for Master and Working Cell Bank
Schneider, KH
PHARMAZEUTISCHE INDUSTRIE, 2005, 67 (11): : 1366 - 1369
[34] FDA's NEPA requirements to continue
Paper Recycler, 1997, 8 (07):
[35] The FDA revises requirements for levothyroxine products
Burman, Kenneth
Hennessey, James
McDermott, Michael
Wartofsky, Leonard
Emerson, Charles
THYROID, 2008, 18 (05) : 487 - 490
[36] FDA Revamps Biosimilar Quality Requirements
Wechsler, Jill
BIOPHARM INTERNATIONAL, 2019, 32 (07) : 6 - 7
[37] FDA cGMP Requirements for PET Drugs
Norenberg, Jeffrey P.
Schwarz, Sally
VanBrocklin, Henry
JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (05) : 16N - 16N
[38] FDA revamps biosimilar quality requirements
Wechsler, Jill
Pharmaceutical Technology, 2019, 43 (07) : 14 - 15
[39] Increased international requirements and FDA cuts
Immel, Barbara K.
BIOPHARM INTERNATIONAL, 2007, 20 (02) : 34 - +
[40] CURRENT STATUS OF FDA TOXICITY REQUIREMENTS
FANCHER, OE
CALANDRA, JC
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1968, 153 (A1) : 258 - &

← 1 2 3 4 5 →